Vanflyta (Quizartinib) for Leukemia

Overview
Vanflyta is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive. This drug is used in combination with standard chemotherapy (cytarabine and anthracycline) during induction and consolidation phases and as maintenance monotherapy following consolidation chemotherapy. Vanflyta is also known by its drug name, quizartinib.

Vanflyta belongs to the kinase inhibitor drug category. It works by inhibiting the activity of the FLT3 protein, which is involved in the growth and survival of certain leukemia cells. By blocking this protein, Vanflyta helps to slow down or stop the growth of cancer cells in individuals with FLT3-ITD-positive AML.

How do I take it?
Prescribing information states that Vanflyta is taken orally as a tablet once daily, with or without food, at approximately the same time each day. The drug is taken as a tablet. Doses may be adjusted if a person is taking other medications or has certain health conditions. Vanflyta should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Vanflyta include decreased lymphocytes (a type of white blood cell), decreased potassium levels, decreased albumin (a protein in the blood), decreased phosphorus levels, increased alkaline phosphatase (an enzyme related to liver and bone health), decreased magnesium levels, febrile neutropenia (fever with low neutrophils, another type of white blood cell), diarrhea, mucositis (inflammation of the mucous membranes), nausea, decreased calcium levels, abdominal pain, sepsis (severe infection), neutropenia (low white blood cell count), headache, increased creatine phosphokinase (an enzyme related to muscle damage), vomiting, and upper respiratory tract infection.

Rare but serious side effects may include QT prolongation (a heart rhythm disorder), torsades de pointes (a type of dangerous arrhythmia), cardiac arrest, and embryo-fetal toxicity (potential harm to an embryo, fetus, or unborn baby). Individuals should be monitored for these conditions, and health care providers may adjust or discontinue treatment if serious side effects occur.

For more information about this treatment, visit:

Label: Vanflyta — Quizartinib Tablet, Film Coated — DailyMed

Vanflyta — Drugs.com